TVRDTvardi Therapeutics Inc. Common Stock

1.860USD-1.06%Mkt Cap: 24.81M $P/E:

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat…